Osteopenia: Is it a problem?

International Journal of Clinical Rheumatology

Volumn 4, Issue 6, 2009, Pages 651-655

  Roux, Christian ^a  

^a Paris Descartes University ^*  (France)

Author keywords

Bone densitometry; Fracture risk; Osteopenia; Osteoporosis; Vertebral fracture

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIUM; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

AGE; BONE DENSITY; CLINICAL DECISION MAKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FALLING; FRACTURE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; LIFESTYLE MODIFICATION; OSTEOPENIA; OSTEOPOROSIS; PATIENT COUNSELING; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VERTEBRA FRACTURE; WEIGHT BEARING;

EID: 77950266682     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.59     Document Type: Review

References (26)

1. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 843, 1-129 (1994).
2. Kanis JA, Mc Closkey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N: A reference standard for the description of osteoporosis. Bone 42, 467-475 (2008).
3. Rimes KA, Salkovskis PM: Prediction of psychological reactions to bone density screening for osteoporosis using a cognitive-behavioral model of health anxiety. Behav. Res. Ther. 40, 359-381 (2002).
4. McClung MR, Wasnich RD, Hosking DJ et al.; on behalf of the Early Postmenopausal Intervention Cohort (EPIC): Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort study. J. Clin. Endocrinol. Metab. 89, 4879-4885 (2004).
5. Abrahamsen B, Vestergaard P, Rud B et al.: Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 21, 796-800 (2006).
6. Wainwright SA, Marshall LM, Ensrud KE et al.; for the Study of Osteoporotic Fractures research group: Hip fracture in women with osteoporosis. J. Clin. Endocrinol. Metab. 90, 2787-2793 (2005).
7. Siris, ES, Miller PD, Barrett-Connor E et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results form the National Osteoporosis Risk Assessment. JAMA 286, 2815-2822 (2001).
8. Netelenbos JC, Lems WF, Geusens PP et al.: Spine radiographs to improve the identification of women at high risk for fractures. Osteoporos. Int. 20(8), 1347-1352 (2009).
9. Miller PD, Barlas S, Brenneman SK et al.: An approach to identifying osteopenic women at increased short-term risk of fracture. Arch. Intern. Med. 164, 1113-1120 (2004).
10. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: scientific review. JAMA 288, 1889-1897 (2002).
11. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH: Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos. Int. 18, 761-770 (2007).
12. Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV: Identification of high-risk individuals for hip fracture: a 14-year prospective study. J. Bone Miner. Res. 20, 1921-1928 (2005).
13. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD: Identification of osteopenic women at high risk of fracture: the OFELY study. J. Bone Miner. Res. 20, 1813-1819 (2005).
14. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA: The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos. Int. 17, 1404-1409 (2006).
15. Hillier TA, Stone KL, Bauer DC et al.: Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women. Arch. Intern. Med. 167, 155-160 (2007).
16. Berger C, Langsetmo L, Joseph L et al.; The CaMos Research Group: Association between change in BMD and fragility fracture in women and men. J. Bone Miner. Res. 24, 361-370 (2009).
17. Kanis JA, Johnell O, Black DM et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33, 293-300 (2003).
18. Seeman E, Devogelaer JP, Lorec R et al.: Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J. Bone Miner. Res. 23, 433-438 (2008).
19. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A: Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos. Int. 19, 681-686 (2008).
20. Cummings SR, Black DM, Thompson DE et al.; for the Fracture Intervention Trial Reserarch Group: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280, 2077-2082 (1998).
21. Ryder KM, Cummings SR, Palermo L et al.; for the Fracture Intervention Trial Research Group: Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J. Gen. Intern. Med. 23(8), 1177-1181 (2008).
22. Quandt SA, Thilpson DE, Schneider DL, Nevitt MC, Black DM, for the Fracture Intervention Trial Research Group: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the fracture intervention trial. Mayo Clin. Proc. 80, 343-349 (2005).
23. Roux C, Thomas T: Optimal use of FRAX. Joint Bone Spine 76(1), 1-3 (2009).
24. Schousboe JT, Nyman JA, Kane RL, Ensrud KE: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann. Intern. Med. 142, 734-741 (2005).
25. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton J: Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic postmenopausal women for animo-bisphosphonate therapy. Osteoporos. Int. 16, 1883-1893 (2005).
26. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd: Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T score > - 2.5 for alendronate therapy: a modelling study. J. Clin. Densitom. 9, 133-143 (2006).